NURS 5334 NURSE PRACTITIONER ADVANCED PHARMACOLOGY
COMPREHENSIVE EXAMINATION STUDY GUIDE: ANTI-INFECTIVE
THERAPEUTICS NEW UPDATE 2026-2027
96 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic and pharmacodynamic principles to optimize anti-infective dosing and minimize
resistance
2 Select appropriate empiric and targeted antimicrobial therapy based on culture data, patient-specific
factors, and guideline recommendations
3 Evaluate and manage adverse drug reactions, drug interactions, and monitoring parameters for
anti-infective agents
4 Integrate antimicrobial stewardship principles into advanced practice nursing decisions across varied
clinical settings
5 Synthesize evidence from current guidelines to prescribe safely in special populations (renal/hepatic
impairment, pregnancy, immunocompromised)
6 NURS 5334 Nurse Practitioner Advanced Pharmacology Comprehensive Examination Study Guide
7 Anti
8 Infective Therapeutics New Update 2026
9 2027
10 Foundations of Advanced Pharmacology - Anti-Infective Therapeutics
11 Applied Advanced Pharmacology - Anti-Infective Therapeutics
12 Advanced Advanced Pharmacology - Anti-Infective Therapeutics
13 Advanced Pharmacology - Anti-Infective Therapeutics Review
ABSTRACT
Page 1
,This study document brings together 96 carefully worded exam questions drawn from NURS 5334
Nurse Practitioner Advanced Pharmacology Comprehensive Examination Study Guide:
Anti-Infective Therapeutics New Update 2026-2027, with the strongest emphasis placed on Apply
pharmacokinetic and pharmacodynamic principles to optimize anti-infective dosing and minimize
resistance, Select appropriate empiric and targeted antimicrobial therapy based on culture data,
patient-specific factors, and guideline recommendations, Evaluate and manage adverse drug
reactions, drug interactions and and monitoring parameters for anti-infective agents. Every item
follows the wording style and level of reasoning you meet in the real paper, and each one is paired
with a clear rationale so the correct choice is never a guess. Work through the set at your own
pace, mark the questions that slow you down, then come back to them until the reasoning feels
automatic. Learners who revise this way walk into the exam room recognising the pattern behind
the questions instead of meeting them for the first time. Keep going - steady, honest practice is
what turns a difficult paper into a comfortable pass.
Q1 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
A patient with vancomycin-resistant Enterococcus faecium bacteremia is
prescribed daptomycin. Which monitoring parameter is most critical to prevent a
serious adverse effect?
A. Serum creatinine kinase levels CORRECT
B. Liver function tests
C. Complete blood count with differential
D. Serum potassium and magnesium
RATIONALE: Daptomycin can cause myopathy, so monitoring creatine kinase (CK) is essential.
Other options are not the primary concern; liver enzymes and CBC are not routinely affected, and
electrolytes are not directly linked to daptomycin toxicity.
Page 2
,Q2 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
Which statement best describes the mechanism by which beta-lactamase
inhibitors restore beta-lactam activity?
A. They irreversibly bind to beta-lactamase enzymes, preventing hydrolysis of the companion
beta-lactam. CORRECT
B. They inhibit efflux pumps, increasing intracellular beta-lactam concentrations.
C. They modify penicillin-binding proteins to increase beta-lactam affinity.
D. They reduce porin expression in Gram-negative bacteria, enhancing drug entry.
RATIONALE: Beta-lactamase inhibitors (e.g., clavulanate, tazobactam, avibactam) act as suicide
substrates that covalently bind beta-lactamases, protecting the beta-lactam antibiotic. Efflux
pump inhibition, PBP modification, and porin changes are not their primary mechanisms.
Q3 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
A patient with invasive aspergillosis is started on voriconazole. Which
pharmacokinetic property most strongly justifies therapeutic drug monitoring for
this agent?
A. Nonlinear, saturable metabolism via CYP2C19 leading to wide interpatient variability
CORRECT
B. Renal elimination unchanged, requiring dose adjustment in CKD
C. High protein binding that displaces other drugs
D. Autoinduction of CYP3A4 resulting in decreased levels over time
RATIONALE: Voriconazole exhibits nonlinear pharmacokinetics due to saturable CYP2C19
metabolism, causing unpredictable plasma concentrations and necessitating TDM. Renal
elimination, protein binding, and autoinduction are not the main reasons for TDM.
Page 3
, Q4 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
In a patient with penicillin allergy who requires prophylaxis for dental procedures,
which alternative is most appropriate according to current guidelines?
A. Clindamycin 600 mg PO 1 hour before procedure
B. Azithromycin 500 mg PO 1 hour before procedure CORRECT
C. Cephalexin 2 g PO 1 hour before procedure
D. Doxycycline 100 mg PO 1 hour before procedure
RATIONALE: Current AHA guidelines recommend azithromycin or clarithromycin for
penicillin-allergic patients. Clindamycin is no longer preferred due to C. difficile risk; cephalexin
has cross-reactivity potential; doxycycline is not recommended for prophylaxis.
Q5 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
Which of the following best explains why rifampin is contraindicated with certain
protease inhibitors in HIV therapy?
A. Rifampin induces CYP3A4, significantly reducing protease inhibitor levels. CORRECT
B. Rifampin inhibits CYP3A4, increasing protease inhibitor toxicity.
C. Rifampin chelates protease inhibitors in the gut, reducing absorption.
D. Rifampin alters gastric pH, decreasing protease inhibitor solubility.
RATIONALE: Rifampin is a potent CYP3A4 inducer, leading to subtherapeutic protease inhibitor
concentrations and risk of HIV resistance. Inhibition, chelation, and pH effects are not the primary
mechanisms.
Page 4
COMPREHENSIVE EXAMINATION STUDY GUIDE: ANTI-INFECTIVE
THERAPEUTICS NEW UPDATE 2026-2027
96 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic and pharmacodynamic principles to optimize anti-infective dosing and minimize
resistance
2 Select appropriate empiric and targeted antimicrobial therapy based on culture data, patient-specific
factors, and guideline recommendations
3 Evaluate and manage adverse drug reactions, drug interactions, and monitoring parameters for
anti-infective agents
4 Integrate antimicrobial stewardship principles into advanced practice nursing decisions across varied
clinical settings
5 Synthesize evidence from current guidelines to prescribe safely in special populations (renal/hepatic
impairment, pregnancy, immunocompromised)
6 NURS 5334 Nurse Practitioner Advanced Pharmacology Comprehensive Examination Study Guide
7 Anti
8 Infective Therapeutics New Update 2026
9 2027
10 Foundations of Advanced Pharmacology - Anti-Infective Therapeutics
11 Applied Advanced Pharmacology - Anti-Infective Therapeutics
12 Advanced Advanced Pharmacology - Anti-Infective Therapeutics
13 Advanced Pharmacology - Anti-Infective Therapeutics Review
ABSTRACT
Page 1
,This study document brings together 96 carefully worded exam questions drawn from NURS 5334
Nurse Practitioner Advanced Pharmacology Comprehensive Examination Study Guide:
Anti-Infective Therapeutics New Update 2026-2027, with the strongest emphasis placed on Apply
pharmacokinetic and pharmacodynamic principles to optimize anti-infective dosing and minimize
resistance, Select appropriate empiric and targeted antimicrobial therapy based on culture data,
patient-specific factors, and guideline recommendations, Evaluate and manage adverse drug
reactions, drug interactions and and monitoring parameters for anti-infective agents. Every item
follows the wording style and level of reasoning you meet in the real paper, and each one is paired
with a clear rationale so the correct choice is never a guess. Work through the set at your own
pace, mark the questions that slow you down, then come back to them until the reasoning feels
automatic. Learners who revise this way walk into the exam room recognising the pattern behind
the questions instead of meeting them for the first time. Keep going - steady, honest practice is
what turns a difficult paper into a comfortable pass.
Q1 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
A patient with vancomycin-resistant Enterococcus faecium bacteremia is
prescribed daptomycin. Which monitoring parameter is most critical to prevent a
serious adverse effect?
A. Serum creatinine kinase levels CORRECT
B. Liver function tests
C. Complete blood count with differential
D. Serum potassium and magnesium
RATIONALE: Daptomycin can cause myopathy, so monitoring creatine kinase (CK) is essential.
Other options are not the primary concern; liver enzymes and CBC are not routinely affected, and
electrolytes are not directly linked to daptomycin toxicity.
Page 2
,Q2 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
Which statement best describes the mechanism by which beta-lactamase
inhibitors restore beta-lactam activity?
A. They irreversibly bind to beta-lactamase enzymes, preventing hydrolysis of the companion
beta-lactam. CORRECT
B. They inhibit efflux pumps, increasing intracellular beta-lactam concentrations.
C. They modify penicillin-binding proteins to increase beta-lactam affinity.
D. They reduce porin expression in Gram-negative bacteria, enhancing drug entry.
RATIONALE: Beta-lactamase inhibitors (e.g., clavulanate, tazobactam, avibactam) act as suicide
substrates that covalently bind beta-lactamases, protecting the beta-lactam antibiotic. Efflux
pump inhibition, PBP modification, and porin changes are not their primary mechanisms.
Q3 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
A patient with invasive aspergillosis is started on voriconazole. Which
pharmacokinetic property most strongly justifies therapeutic drug monitoring for
this agent?
A. Nonlinear, saturable metabolism via CYP2C19 leading to wide interpatient variability
CORRECT
B. Renal elimination unchanged, requiring dose adjustment in CKD
C. High protein binding that displaces other drugs
D. Autoinduction of CYP3A4 resulting in decreased levels over time
RATIONALE: Voriconazole exhibits nonlinear pharmacokinetics due to saturable CYP2C19
metabolism, causing unpredictable plasma concentrations and necessitating TDM. Renal
elimination, protein binding, and autoinduction are not the main reasons for TDM.
Page 3
, Q4 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
In a patient with penicillin allergy who requires prophylaxis for dental procedures,
which alternative is most appropriate according to current guidelines?
A. Clindamycin 600 mg PO 1 hour before procedure
B. Azithromycin 500 mg PO 1 hour before procedure CORRECT
C. Cephalexin 2 g PO 1 hour before procedure
D. Doxycycline 100 mg PO 1 hour before procedure
RATIONALE: Current AHA guidelines recommend azithromycin or clarithromycin for
penicillin-allergic patients. Clindamycin is no longer preferred due to C. difficile risk; cephalexin
has cross-reactivity potential; doxycycline is not recommended for prophylaxis.
Q5 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
ANTI-INFECTIVE DOSING AND MINIMIZE RESISTANCE
Which of the following best explains why rifampin is contraindicated with certain
protease inhibitors in HIV therapy?
A. Rifampin induces CYP3A4, significantly reducing protease inhibitor levels. CORRECT
B. Rifampin inhibits CYP3A4, increasing protease inhibitor toxicity.
C. Rifampin chelates protease inhibitors in the gut, reducing absorption.
D. Rifampin alters gastric pH, decreasing protease inhibitor solubility.
RATIONALE: Rifampin is a potent CYP3A4 inducer, leading to subtherapeutic protease inhibitor
concentrations and risk of HIV resistance. Inhibition, chelation, and pH effects are not the primary
mechanisms.
Page 4
